Tom H. Karlsen

24.6k total citations · 7 hit papers
170 papers, 9.5k citations indexed

About

Tom H. Karlsen is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Tom H. Karlsen has authored 170 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Hepatology, 73 papers in Surgery and 63 papers in Epidemiology. Recurrent topics in Tom H. Karlsen's work include Liver Diseases and Immunity (100 papers), Liver Disease Diagnosis and Treatment (59 papers) and Pediatric Hepatobiliary Diseases and Treatments (37 papers). Tom H. Karlsen is often cited by papers focused on Liver Diseases and Immunity (100 papers), Liver Disease Diagnosis and Treatment (59 papers) and Pediatric Hepatobiliary Diseases and Treatments (37 papers). Tom H. Karlsen collaborates with scholars based in Norway, Germany and United Kingdom. Tom H. Karlsen's co-authors include Kirsten Muri Boberg, Johannes R. Hov, Mette Vesterhus, Trine Folseraas, Gideon M. Hirschfield, Erik Schrumpf, André Franke, Espen Melum, Douglas Thorburn and Raúl J. Andrade and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Nature Genetics.

In The Last Decade

Tom H. Karlsen

164 papers receiving 9.4k citations

Hit Papers

EASL Clinical Practice Gu... 2013 2026 2017 2021 2019 2017 2013 2019 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL Clinical Practice Guidelines: Drug-induced liver injury
    2019 710 citations Raúl J. Andrade, Guruprasad P. Aithal et al. Journal of Hepatology profile →
  2. Primary sclerosing cholangitis – a comprehensive review
    2017 527 citations Tom H. Karlsen, Trine Folseraas et al. Journal of Hepatology profile →
  3. Primary sclerosing cholangitis
    2013 402 citations Gideon M. Hirschfield, Tom H. Karlsen et al. profile →
  4. Cholangiocyte pathobiology
    2019 339 citations Tom H. Karlsen, Nicholas F. LaRusso et al. profile →
  5. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation
    2015 285 citations Espen Melum, Tom H. Karlsen et al. profile →
  6. EASL Clinical Practice Guidelines on sclerosing cholangitis
    2022 175 citations Olivier Chazouillères, Ulrich Beuers et al. Journal of Hepatology profile →
  7. Primary sclerosing cholangitis
    2025 13 citations Annika Bergquist, Tom H. Karlsen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom H. Karlsen Norway 54 4.9k 3.5k 3.5k 1.8k 1.8k 170 9.5k
Andrew D. Clouston Australia 57 3.8k 0.8× 2.7k 0.8× 4.9k 1.4× 969 0.5× 1.4k 0.8× 197 11.4k
Angelo Andriulli Italy 63 4.0k 0.8× 5.9k 1.7× 4.6k 1.3× 3.0k 1.7× 1.5k 0.8× 382 13.5k
Kiwamu Okita Japan 56 6.7k 1.4× 3.3k 0.9× 4.7k 1.3× 1.9k 1.0× 2.3k 1.3× 297 12.4k
Mario Strazzabosco Italy 52 3.5k 0.7× 4.1k 1.2× 2.3k 0.7× 1.2k 0.6× 1.7k 1.0× 226 8.4k
Joel K. Greenson United States 63 3.6k 0.7× 4.3k 1.2× 5.7k 1.6× 2.1k 1.2× 2.9k 1.6× 201 15.8k
Jürgen Klempnauer Germany 50 3.4k 0.7× 4.8k 1.3× 2.2k 0.6× 1.6k 0.9× 963 0.5× 296 8.7k
Swan N. Thung United States 69 7.5k 1.5× 4.3k 1.2× 6.4k 1.8× 1.6k 0.9× 4.2k 2.4× 320 17.0k
Fabio Farinati Italy 58 5.9k 1.2× 3.2k 0.9× 5.0k 1.4× 1.7k 1.0× 1.8k 1.0× 328 11.3k
Björn Nashan Germany 55 2.7k 0.6× 5.3k 1.5× 2.7k 0.8× 1.1k 0.6× 1.8k 1.0× 377 12.8k
James G. Kench Australia 50 3.7k 0.8× 2.5k 0.7× 6.4k 1.8× 1.5k 0.8× 2.6k 1.5× 168 11.9k

Countries citing papers authored by Tom H. Karlsen

Since Specialization
Citations

This map shows the geographic impact of Tom H. Karlsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom H. Karlsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom H. Karlsen more than expected).

Fields of papers citing papers by Tom H. Karlsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom H. Karlsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom H. Karlsen. The network helps show where Tom H. Karlsen may publish in the future.

Co-authorship network of co-authors of Tom H. Karlsen

This figure shows the co-authorship network connecting the top 25 collaborators of Tom H. Karlsen. A scholar is included among the top collaborators of Tom H. Karlsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom H. Karlsen. Tom H. Karlsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Mingyi, Mari Kaarbø, Henrik M. Reims, et al.. (2024). Altered Genome-Wide DNA Methylation in the Duodenum of Common Variable Immunodeficiency Patients. Journal of Clinical Immunology. 44(6). 133–133. 1 indexed citations
2.
Kücken, Michael, Urška Repnik, Sarah Seifert, et al.. (2023). Apical bulkheads accumulate as adaptive response to impaired bile flow in liver disease. EMBO Reports. 24(9). e57181–e57181. 7 indexed citations
3.
Juran, Brian D., Ahmad H. Ali, Erik M. Schlicht, et al.. (2023). Environmental chemicals and endogenous metabolites in bile of USA and Norway patients with primary sclerosing cholangitis. PubMed. 3(1). osac011–osac011. 2 indexed citations
4.
Wacker, Eike Matthias, Florian Uellendahl-Werth, Olaf Wolkenhauer, et al.. (2023). Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis. JHEP Reports. 6(2). 100988–100988. 2 indexed citations
5.
Meer, Dennis van der, Tiril P. Gurholt, Ida E. Sønderby, et al.. (2022). The link between liver fat and cardiometabolic diseases is highlighted by genome-wide association study of MRI-derived measures of body composition. Communications Biology. 5(1). 1271–1271. 8 indexed citations
6.
Valestrand, Laura, Simen H. Hansen, Jonas Øgaard, et al.. (2022). Bile from Patients with Primary Sclerosing Cholangitis Contains Mucosal-Associated Invariant T-Cell Antigens. American Journal Of Pathology. 192(4). 629–641. 18 indexed citations
7.
Vesterhus, Mette, Kristin Kaasen Jørgensen, Svein Oskar Frigstad, John Willy Haukeland, & Tom H. Karlsen. (2022). Vi trenger en ny strategi for leversykdom. Tidsskrift for Den norske legeforening. 142(3). 2 indexed citations
8.
Rupp, Christian, Annika Bergquist, Trine Folseraas, et al.. (2021). Associations of neopterin and kynurenine–tryptophan ratio with survival in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology. 56(4). 443–452. 9 indexed citations
9.
Jiang, Xiaojun, Annika Bergquist, Britt-Sabina Löscher, et al.. (2021). A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis. Science Translational Medicine. 13(582). 15 indexed citations
10.
Mousa, Omar Y., Brian D. Juran, Bryan M. McCauley, et al.. (2020). Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology. 74(1). 281–295. 68 indexed citations
11.
Dhillon, Amandeep K., Andreas E. Kremer, Martin Kummen, et al.. (2019). Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. Scientific Reports. 9(1). 8450–8450. 7 indexed citations
12.
Schneditz, Georg, Ester Pagano, M. Zaeem Cader, et al.. (2019). GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Science Signaling. 12(562). 65 indexed citations
13.
Andrade, Raúl J., Guruprasad P. Aithal, Einar S. Björnsson, et al.. (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology. 70(6). 1222–1261. 710 indexed citations breakdown →
14.
Aabakken, Lars, Tom H. Karlsen, Jörg Albert, et al.. (2017). Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Journal of Hepatology. 66(6). 1265–1281. 68 indexed citations
15.
Aandahl, Einar Martin, William Bennet, Michael Olausson, et al.. (2015). Transplantation With Livers From Deceased Donors Older Than 75 Years. Transplantation. 99(12). 2534–2542. 22 indexed citations
16.
Berntsen, Natalie Lie, Kirsten Muri Boberg, Tom H. Karlsen, et al.. (2013). Predictors of liver transplantation outcomes. Hepatology. 58(S1). 253A–256A. 1 indexed citations
17.
Karlsen, Tom H. & Kirsten Muri Boberg. (2013). Update on primary sclerosing cholangitis. Journal of Hepatology. 59(3). 571–582. 84 indexed citations
18.
Holm, Kristian, Espen Melum, André Franke, & Tom H. Karlsen. (2010). SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics. 11(1). 600–600. 76 indexed citations
19.
Vik, Erik Sebastian, Bjørn Dalhus, Tom H. Karlsen, et al.. (2009). Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis. 30(7). 1147–1154. 41 indexed citations
20.
Hov, Johannes R., Kirsten Muri Boberg, & Tom H. Karlsen. (2008). Autoantibodies in primary sclerosing cholangitis. World Journal of Gastroenterology. 14(24). 3781–3781. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew D. Clouston Breakdown of academic impact, for papers by Angelo Andriulli Breakdown of academic impact, for papers by Kiwamu Okita Breakdown of academic impact, for papers by Mario Strazzabosco Breakdown of academic impact, for papers by Joel K. Greenson Breakdown of academic impact, for papers by Jürgen Klempnauer Breakdown of academic impact, for papers by Swan N. Thung Breakdown of academic impact, for papers by Fabio Farinati Breakdown of academic impact, for papers by Björn Nashan Breakdown of academic impact, for papers by James G. Kench
Rankless by CCL
2026